Idera Pharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
30 Novembro 2006 - 11:15AM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced that Robert
Karr, M.D., President of Idera, will discuss the Company�s
Toll-Like Receptor - targeted drug discovery and development
programs and provide a general corporate overview at the BMO
Capital Markets Focus on Healthcare Conference to be held at the
Millennium Broadway Hotel in New York City. The presentation will
begin at 11:00 a.m. (ET) on Thursday, December 7, 2006. The
presentation will be available via live audio webcast on the
Company�s website at www.iderapharma.com and can be found under
http://iderapharma.com/webcasts.php. Archived replays will also be
located on the Company�s site following the event. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company that is developing drug candidates to treat
cancer and infectious, respiratory, and autoimmune diseases, and
for use as vaccine adjuvants. Idera�s proprietary drug candidates
are designed to modulate TLRs, the body�s first line of immune
defense. Idera�s pioneering DNA chemistry expertise enables it to
identify drug candidates for internal development and creates
opportunities for multiple collaborative alliances. Idera�s most
advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonists for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera�s
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera�s technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company�s
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company�s technology and prevent others from
infringing it; whether Idera�s cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera�s Quarterly Report on Form 10-Q filed on November 13,
2006, which important factors are incorporated herein by reference.
Idera disclaims any intention or obligation to update any
forward-looking statements. Idera Pharmaceuticals, Inc. (AMEX: IDP)
today announced that Robert Karr, M.D., President of Idera, will
discuss the Company's Toll-Like Receptor - targeted drug discovery
and development programs and provide a general corporate overview
at the BMO Capital Markets Focus on Healthcare Conference to be
held at the Millennium Broadway Hotel in New York City. The
presentation will begin at 11:00 a.m. (ET) on Thursday, December 7,
2006. The presentation will be available via live audio webcast on
the Company's website at www.iderapharma.com and can be found under
http://iderapharma.com/webcasts.php. Archived replays will also be
located on the Company's site following the event. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company that is developing drug candidates to treat
cancer and infectious, respiratory, and autoimmune diseases, and
for use as vaccine adjuvants. Idera's proprietary drug candidates
are designed to modulate TLRs, the body's first line of immune
defense. Idera's pioneering DNA chemistry expertise enables it to
identify drug candidates for internal development and creates
opportunities for multiple collaborative alliances. Idera's most
advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonists for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company's technology and prevent others from
infringing it; whether Idera's cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera's Quarterly Report on Form 10-Q filed on November 13,
2006, which important factors are incorporated herein by reference.
Idera disclaims any intention or obligation to update any
forward-looking statements.
Idera Pharmaceutical (AMEX:IDP)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Idera Pharmaceutical (AMEX:IDP)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024